Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Stephen R Fussell. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Stephen R Fussell har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ABT / Abbott Laboratories | Executive Vice President | 113 227 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Stephen R Fussell. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Stephen R Fussell som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-04-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −56 000 | 113 227 | −33,09 | ||||
2019-04-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −56 000 | 169 935 | −24,79 | 76,00 | −4 256 000 | 12 915 060 | |
2019-04-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 56 000 | 225 935 | 32,95 | 47,00 | 2 632 000 | 10 618 945 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 246 | 169 935 | −1,30 | 78,00 | −175 188 | 13 254 930 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −15 221 | 172 181 | −8,12 | 77,23 | −1 175 518 | 13 297 539 | |
2019-02-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 138 121 | 138 121 | |||||
2019-02-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 26 350 | 187 402 | 16,36 | ||||
2018-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −11 106 | 161 052 | −6,45 | 60,13 | −667 804 | 9 684 057 | |
2018-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −12 726 | 172 158 | −6,88 | 60,55 | −770 559 | 10 424 167 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −104 642 | 104 642 | −50,00 | ||||
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 233 125 | −0,04 | 59,67 | −5 967 | 13 910 336 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −77 | 233 225 | −0,03 | 59,67 | −4 594 | 13 916 069 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 985 | 233 302 | −1,26 | 59,66 | −178 100 | 13 919 964 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −8 206 | 236 287 | −3,36 | 59,66 | −489 570 | 14 096 882 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −10 | 244 493 | 0,00 | 59,66 | −597 | 14 585 841 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 200 | 244 503 | −1,29 | 59,66 | −190 896 | 14 585 826 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 794 | 247 703 | −1,90 | 59,65 | −285 962 | 14 775 484 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 252 497 | −0,24 | 59,64 | −35 787 | 15 060 184 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 700 | 253 097 | −0,67 | 59,64 | −101 388 | 15 094 705 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 254 797 | −0,20 | 59,64 | −29 818 | 15 194 819 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 600 | 255 297 | −0,62 | 59,63 | −95 408 | 15 223 360 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −22 500 | 256 897 | −8,05 | 59,60 | −1 341 000 | 15 311 061 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 279 397 | −0,04 | 59,60 | −5 960 | 16 650 664 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 279 497 | −0,18 | 59,59 | −29 795 | 16 655 226 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 279 997 | −0,18 | 59,58 | −29 792 | 16 683 621 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 280 497 | −0,18 | 59,58 | −29 790 | 16 712 011 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −180 | 280 997 | −0,06 | 59,56 | −10 721 | 16 736 181 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −574 | 281 177 | −0,20 | 59,54 | −34 179 | 16 742 684 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −226 | 281 751 | −0,08 | 59,54 | −13 456 | 16 775 455 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −989 | 281 977 | −0,35 | 59,53 | −58 875 | 16 786 091 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −728 | 282 966 | −0,26 | 59,52 | −43 331 | 16 842 136 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 283 694 | −0,07 | 59,52 | −11 903 | 16 884 048 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 172 | 283 894 | −0,41 | 59,51 | −69 746 | 16 894 532 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 200 | 285 066 | −0,42 | 59,50 | −71 400 | 16 961 427 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −441 | 286 266 | −0,15 | 59,50 | −26 237 | 17 031 396 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 419 | 286 707 | −0,49 | 59,49 | −84 416 | 17 056 199 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 288 126 | −0,10 | 59,48 | −17 844 | 17 137 734 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 100 | 288 426 | −0,38 | 59,47 | −65 417 | 17 152 694 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 104 642 | 289 526 | 56,60 | 38,40 | 4 018 253 | 11 117 798 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 246 963 | 246 963 | |||||
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 44 909 | 184 884 | 32,08 | ||||
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −900 | 184 884 | −0,48 | 59,86 | −53 874 | 11 067 156 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 185 784 | −0,05 | 59,86 | −5 986 | 11 120 566 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −400 | 185 884 | −0,21 | 59,86 | −23 942 | 11 126 087 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 000 | 186 284 | −0,53 | 59,85 | −59 850 | 11 149 097 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 100 | 187 284 | −0,58 | 59,84 | −65 824 | 11 207 075 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 832 | 188 384 | −0,96 | 59,83 | −109 609 | 11 271 015 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 190 216 | −0,11 | 59,82 | −11 964 | 11 378 721 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 200 | 190 416 | −0,63 | 59,82 | −71 778 | 11 389 733 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 191 616 | −0,05 | 59,81 | −5 981 | 11 460 553 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 191 716 | −0,05 | 59,81 | −5 981 | 11 466 055 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 500 | 191 816 | −0,78 | 59,80 | −89 700 | 11 470 597 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 193 316 | −0,10 | 59,80 | −11 959 | 11 559 330 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 193 516 | −0,31 | 59,79 | −35 874 | 11 570 322 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −304 | 194 116 | −0,16 | 59,78 | −18 175 | 11 605 225 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −900 | 194 420 | −0,46 | 59,78 | −53 802 | 11 622 428 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 300 | 195 320 | −0,66 | 59,78 | −77 708 | 11 675 253 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 500 | 196 620 | −1,26 | 59,77 | −149 425 | 11 751 977 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −740 | 199 120 | −0,37 | 59,76 | −44 226 | 11 900 407 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 419 | 199 860 | −1,68 | 59,76 | −204 319 | 11 943 634 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 700 | 203 279 | −0,83 | 59,76 | −101 584 | 12 146 937 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 100 | 204 979 | −1,49 | 59,75 | −185 225 | 12 247 495 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −106 | 208 079 | −0,05 | 59,74 | −6 333 | 12 431 680 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 208 185 | −0,29 | 59,74 | −35 844 | 12 436 972 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −116 | 208 785 | −0,06 | 59,74 | −6 929 | 12 471 772 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 600 | 208 901 | −0,76 | 59,73 | −95 568 | 12 477 657 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 210 501 | −0,05 | 59,73 | −5 973 | 12 572 698 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −628 | 210 601 | −0,30 | 59,72 | −37 507 | 12 578 145 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 294 | 211 229 | −0,61 | 59,72 | −77 278 | 12 614 596 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 900 | 212 523 | −1,35 | 59,71 | −173 159 | 12 689 748 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 215 423 | −0,09 | 59,70 | −11 941 | 12 861 830 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 900 | 215 623 | −0,87 | 59,70 | −113 430 | 12 872 693 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −901 | 217 523 | −0,41 | 59,70 | −53 785 | 12 985 035 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 300 | 218 424 | −1,04 | 59,69 | −137 287 | 13 037 729 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 999 | 220 724 | −1,34 | 59,68 | −178 995 | 13 173 912 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 774 | 223 723 | −1,22 | 59,68 | −165 552 | 13 351 789 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 226 497 | −0,26 | 59,68 | −35 805 | 13 516 208 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −6 028 | 227 097 | −2,59 | 59,67 | −359 691 | 13 550 878 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 139 975 | −0,14 | 62,89 | −12 578 | 8 803 028 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 140 175 | −0,43 | 62,87 | −37 722 | 8 812 802 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −700 | 140 775 | −0,49 | 62,86 | −44 002 | 8 849 116 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 141 475 | −0,42 | 62,86 | −37 713 | 8 892 411 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 400 | 142 075 | −0,98 | 62,85 | −87 990 | 8 929 414 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 198 | 143 475 | −0,83 | 62,84 | −75 288 | 9 016 686 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 502 | 144 673 | −2,36 | 62,84 | −220 066 | 9 091 251 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −662 | 148 175 | −0,44 | 62,84 | −41 597 | 9 310 576 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 506 | 148 837 | −2,30 | 62,83 | −220 282 | 9 351 429 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −945 | 152 343 | −0,62 | 62,82 | −59 370 | 9 570 949 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 500 | 153 288 | −2,23 | 62,82 | −219 870 | 9 629 552 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 394 | 156 788 | −1,50 | 62,82 | −150 379 | 9 848 638 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 008 | 159 182 | −1,85 | 62,81 | −188 932 | 9 998 221 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −799 | 162 190 | −0,49 | 62,80 | −50 181 | 10 186 343 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −900 | 162 989 | −0,55 | 62,80 | −56 520 | 10 235 709 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 163 889 | −0,12 | 62,80 | −12 559 | 10 291 410 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −331 | 164 089 | −0,20 | 62,79 | −20 783 | 10 303 148 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −700 | 164 420 | −0,42 | 62,78 | −43 946 | 10 322 288 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −499 | 165 120 | −0,30 | 62,78 | −31 325 | 10 365 408 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 103 | 165 619 | −1,25 | 62,77 | −132 005 | 10 395 905 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 270 | 167 722 | −0,75 | 62,76 | −79 712 | 10 527 071 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 400 | 168 992 | −1,40 | 62,76 | −150 624 | 10 605 938 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 231 | 171 392 | −0,71 | 62,76 | −77 251 | 10 755 705 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 300 | 172 623 | −1,31 | 62,75 | −144 325 | 10 832 093 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −497 | 174 923 | −0,28 | 62,74 | −31 184 | 10 975 544 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 690 | 175 420 | −2,06 | 62,74 | −231 511 | 11 005 851 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −303 | 179 110 | −0,17 | 62,74 | −19 009 | 11 236 466 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −307 | 179 413 | −0,17 | 62,73 | −19 258 | 11 254 577 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 179 720 | −0,06 | 62,72 | −6 272 | 11 272 937 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −400 | 179 820 | −0,22 | 62,72 | −25 088 | 11 278 310 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −103 | 180 220 | −0,06 | 62,72 | −6 460 | 11 302 497 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 180 323 | −0,11 | 62,70 | −12 541 | 11 307 154 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −103 | 180 523 | −0,06 | 62,70 | −6 458 | 11 318 792 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −400 | 180 626 | −0,22 | 62,69 | −25 076 | 11 323 444 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 181 026 | −0,17 | 62,68 | −18 804 | 11 346 710 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 181 326 | −0,17 | 62,66 | −18 798 | 11 361 887 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 181 626 | −0,16 | 62,65 | −18 795 | 11 378 869 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 181 926 | −0,05 | 62,64 | −6 264 | 11 395 845 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −112 | 182 026 | −0,06 | 62,62 | −7 013 | 11 398 468 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 182 138 | −0,11 | 62,95 | −12 590 | 11 465 587 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 000 | 182 338 | −0,55 | 62,94 | −62 940 | 11 476 354 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 100 | 183 338 | −1,13 | 62,93 | −132 153 | 11 537 460 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −7 577 | 185 438 | −3,93 | 62,92 | −476 745 | 11 667 759 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −745 | 193 015 | −0,38 | 62,91 | −46 868 | 12 142 574 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −755 | 193 760 | −0,39 | 62,90 | −47 490 | 12 187 504 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 200 | 194 515 | −1,12 | 62,89 | −138 358 | 12 233 048 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 196 715 | −0,25 | 62,88 | −31 442 | 12 370 423 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 702 | 197 215 | −0,86 | 62,88 | −107 022 | 12 400 879 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −504 | 198 917 | −0,25 | 62,88 | −31 689 | 12 506 906 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 790 | 199 421 | −1,38 | 62,87 | −175 407 | 12 537 598 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −102 | 202 211 | −0,05 | 62,86 | −6 412 | 12 711 995 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 202 313 | −0,39 | 62,86 | −50 288 | 12 717 395 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −17 200 | 203 113 | −7,81 | 62,86 | −1 081 106 | 12 766 668 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 400 | 220 313 | −1,08 | 62,85 | −150 840 | 13 846 672 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 851 | 222 713 | −0,82 | 62,84 | −116 326 | 13 996 398 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 502 | 224 564 | −1,54 | 62,84 | −220 066 | 14 111 602 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 404 | 228 066 | −1,04 | 62,84 | −151 055 | 14 330 527 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −20 796 | 230 470 | −8,28 | 62,83 | −1 306 613 | 14 480 430 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 702 | 251 266 | −0,67 | 62,82 | −106 928 | 15 785 786 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −6 398 | 252 968 | −2,47 | 62,82 | −401 922 | 15 891 450 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −700 | 259 366 | −0,27 | 62,82 | −43 972 | 16 292 724 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −41 413 | 260 066 | −13,74 | 62,82 | −2 601 358 | 16 336 046 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 297 | 301 479 | −0,76 | 62,81 | −144 275 | 18 935 896 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −18 700 | 303 776 | −5,80 | 62,80 | −1 174 454 | 19 078 652 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 683 | 322 476 | −1,13 | 62,80 | −231 292 | 20 251 493 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 326 159 | −0,09 | 62,80 | −18 839 | 20 481 970 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −12 125 | 326 459 | −3,58 | 62,80 | −761 389 | 20 499 993 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 225 | 338 584 | −1,23 | 62,79 | −265 288 | 21 259 689 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −400 | 342 809 | −0,12 | 62,79 | −25 115 | 21 524 120 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 343 209 | −0,15 | 62,78 | −31 392 | 21 548 377 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 000 | 561 518 | −0,18 | 62,68 | −62 680 | 35 195 948 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −104 642 | 209 284 | −33,33 | ||||
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −134 741 | 0 | −100,00 | ||||
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −149 600 | 0 | −100,00 | ||||
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −32 143 | 343 709 | −8,55 | 62,78 | −2 017 938 | 21 578 051 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 375 852 | −0,21 | 62,78 | −50 222 | 23 595 049 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 328 | 376 652 | −0,35 | 62,78 | −83 365 | 23 644 329 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −6 986 | 377 980 | −1,81 | 62,77 | −438 511 | 23 725 805 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 384 966 | −0,21 | 62,77 | −50 214 | 24 163 353 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 886 | 385 766 | −1,25 | 62,76 | −306 670 | 24 212 603 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 703 | 390 652 | −0,94 | 62,76 | −232 400 | 24 517 320 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 724 | 394 355 | −1,18 | 62,76 | −296 455 | 24 747 748 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −53 383 | 399 079 | −11,80 | 62,75 | −3 349 783 | 25 042 207 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 615 | 452 462 | −0,57 | 62,75 | −164 085 | 28 390 859 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −83 546 | 455 077 | −15,51 | 62,74 | −5 242 094 | 28 553 806 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −8 400 | 538 623 | −1,54 | 62,74 | −527 016 | 33 793 207 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 017 | 547 023 | −0,73 | 62,74 | −252 006 | 34 317 488 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −5 903 | 551 040 | −1,06 | 62,73 | −370 295 | 34 566 739 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 010 | 556 943 | −0,54 | 62,72 | −188 802 | 34 934 250 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −9 | 559 953 | 0,00 | 62,72 | −564 | 35 117 452 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 559 962 | −0,02 | 62,71 | −6 271 | 35 115 217 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 560 062 | −0,09 | 62,70 | −31 352 | 35 118 688 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −356 | 560 562 | −0,06 | 62,70 | −22 321 | 35 147 237 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 560 918 | −0,05 | 62,70 | −18 808 | 35 166 754 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 561 218 | −0,05 | 62,68 | −18 806 | 35 179 950 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 562 518 | −0,02 | 62,68 | −6 268 | 35 255 816 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 562 618 | −0,05 | 62,66 | −18 800 | 35 256 457 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 303 | 562 918 | −0,58 | 62,66 | −206 966 | 35 272 442 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 566 221 | −0,09 | 62,66 | −31 328 | 35 476 577 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 400 | 566 721 | −0,77 | 62,65 | −275 660 | 35 505 071 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 104 642 | 571 121 | 22,43 | 38,40 | 4 018 253 | 21 931 046 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 134 741 | 466 479 | 40,62 | 39,12 | 5 271 068 | 18 248 658 | |
2018-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 149 600 | 331 738 | 82,14 | 34,94 | 5 227 024 | 11 590 926 | |
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −44 000 | 0 | −100,00 | ||||
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −45 800 | 0 | −100,00 | ||||
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −28 700 | 0 | −100,00 | ||||
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −38 700 | 0 | −100,00 | ||||
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −39 350 | 0 | −100,00 | ||||
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −196 550 | 182 138 | −51,90 | 49,50 | −9 729 225 | 9 015 831 | |
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 44 000 | 378 688 | 13,15 | 27,03 | 1 189 478 | 10 237 300 | |
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 45 800 | 334 688 | 15,85 | 22,39 | 1 025 549 | 7 494 300 | |
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 28 700 | 288 888 | 11,03 | 26,19 | 751 593 | 7 565 370 | |
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 38 700 | 260 188 | 17,47 | 26,02 | 1 006 780 | 6 768 791 | |
2017-08-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 39 350 | 221 488 | 21,60 | 26,70 | 1 050 539 | 5 913 132 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −44 000 | 0 | −100,00 | ||||
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −45 800 | 0 | −100,00 | ||||
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −28 700 | 0 | −100,00 | ||||
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −38 700 | 0 | −100,00 | ||||
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −39 350 | 0 | −100,00 | ||||
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −195 700 | 182 138 | −51,79 | 46,00 | −9 002 200 | 8 378 348 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 377 838 | −0,08 | 46,01 | −13 803 | 17 384 326 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 378 138 | −0,13 | 46,02 | −23 010 | 17 401 911 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −50 | 378 638 | −0,01 | 46,93 | −2 347 | 17 769 860 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 44 000 | 378 688 | 13,15 | 27,03 | 1 189 478 | 10 237 300 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 45 800 | 334 688 | 15,85 | 22,39 | 1 025 549 | 7 494 300 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 28 700 | 288 888 | 11,03 | 26,19 | 751 593 | 7 565 370 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 38 700 | 260 188 | 17,47 | 26,02 | 1 006 780 | 6 768 791 | |
2017-06-09 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 39 350 | 221 488 | 21,60 | 26,70 | 1 050 539 | 5 913 132 | |
2017-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −11 380 | 182 138 | −5,88 | 45,46 | −517 335 | 8 279 993 | |
2017-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 182 242 | 182 242 | |||||
2017-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 26 351 | 193 518 | 15,76 | ||||
2017-02-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
P - Purchase | 12 200 | 167 167 | 7,87 | 40,77 | 497 394 | 6 815 399 | |
2016-07-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −41 500 | 0 | −100,00 | ||||
2016-07-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −7 000 | 154 967 | −4,32 | 45,02 | −315 140 | 6 976 614 | |
2016-07-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −34 500 | 161 967 | −17,56 | 45,00 | −1 552 500 | 7 288 515 | |
2016-07-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 41 500 | 196 467 | 26,78 | 25,25 | 1 047 713 | 4 960 026 | |
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 340 | 154 967 | −0,86 | 39,26 | −52 610 | 6 084 159 | |
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −62 | 156 307 | −0,04 | 39,26 | −2 434 | 6 137 394 | |
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −10 039 | 156 369 | −6,03 | 39,52 | −396 741 | 6 179 703 | |
2016-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 313 926 | 313 926 | |||||
2016-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 35 807 | 166 408 | 27,42 | ||||
2015-08-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 130 601 | −0,23 | 50,48 | −15 142 | 6 592 085 | |
2015-08-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 300 | 130 901 | −0,98 | 50,47 | −65 614 | 6 606 835 | |
2015-08-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 000 | 132 201 | −0,75 | 50,47 | −50 470 | 6 672 184 | |
2015-08-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 133 201 | −0,08 | 50,46 | −5 046 | 6 721 589 | |
2015-08-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −10 396 | 133 301 | −7,23 | 50,46 | −524 582 | 6 726 368 | |
2015-08-13 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −41 500 | 0 | −100,00 | ||||
2015-08-13 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −28 404 | 143 697 | −16,50 | 50,66 | −1 438 947 | 7 279 690 | |
2015-08-13 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 41 500 | 172 101 | 31,78 | 21,22 | 880 605 | 3 651 880 | |
2015-03-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −11 459 | 130 601 | −8,07 | 47,61 | −545 563 | 6 217 914 | |
2015-02-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 169 227 | 169 227 | |||||
2015-02-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 24 015 | 142 060 | 20,34 | ||||
2014-09-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −17 400 | 0 | −100,00 | ||||
2014-09-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −14 500 | 0 | −100,00 | ||||
2014-09-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −23 619 | 118 045 | −16,67 | 43,38 | −1 024 592 | 5 120 792 | |
2014-09-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 17 400 | 141 664 | 14,00 | 23,22 | 404 000 | 3 289 211 | |
2014-09-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 14 500 | 124 264 | 13,21 | 22,27 | 322 872 | 2 766 986 | |
2014-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −13 414 | 109 764 | −10,89 | 39,79 | −533 743 | 4 367 510 | |
2014-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 134 741 | 134 741 | |||||
2014-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Common Shares without par value |
A - Award | 22 009 | 123 178 | 21,75 | ||||
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −1 227 | 0 | −100,00 | ||||
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −642 | 101 169 | −0,63 | 37,64 | −24 165 | 3 808 001 | |
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 1 227 | 101 811 | 1,22 | 19,72 | 24 192 | 2 007 336 | |
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −7 558 | 0 | −100,00 | ||||
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −2 908 | 0 | −100,00 | ||||
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −10 466 | 100 584 | −9,42 | 37,59 | −393 417 | 3 780 953 | |
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 7 558 | 111 050 | 7,30 | 25,17 | 190 266 | 2 795 584 | |
2013-11-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 2 908 | 103 492 | 2,89 | 25,52 | 74 226 | 2 641 613 | |
2013-03-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −11 974 | 100 584 | −10,64 | 34,26 | −410 229 | 3 446 008 | |
2013-02-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −666 | 112 558 | −0,59 | 34,80 | −23 177 | 3 917 131 | |
2013-02-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 400 | 113 224 | −2,08 | 34,80 | −83 525 | 3 940 422 | |
2013-02-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −8 269 | 115 624 | −6,67 | 35,08 | −290 077 | 4 056 090 | |
2013-02-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 149 600 | 149 600 | |||||
2013-02-20 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 28 800 | 123 893 | 30,29 | ||||
2013-02-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −9 690 | 0 | −100,00 | ||||
2013-02-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −9 690 | 95 093 | −9,25 | 33,89 | −328 394 | 3 222 702 | |
2013-02-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 9 690 | 104 783 | 10,19 | 31,90 | 309 123 | 3 342 703 | |
2012-10-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −5 948 | 0 | −100,00 | ||||
2012-10-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 000 | 95 093 | −2,06 | 66,00 | −132 000 | 6 276 138 | |
2012-10-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −5 948 | 97 093 | −5,77 | 66,00 | −392 568 | 6 408 138 | |
2012-10-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 5 948 | 103 041 | 6,13 | 60,39 | 359 200 | 6 222 646 | |
2012-08-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 9 690 | 9 690 | |||||
2012-08-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −10 988 | 0 | −100,00 | ||||
2012-08-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −9 690 | 97 093 | −9,07 | 66,39 | −643 319 | 6 446 004 | |
2012-08-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 10 988 | 106 783 | 11,47 | 53,00 | 582 364 | 5 659 499 | |
2012-07-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −2 275 | 0 | −100,00 | ||||
2012-07-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 275 | 95 795 | −2,32 | 64,42 | −146 558 | 6 171 210 | |
2012-07-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 2 275 | 98 070 | 2,37 | 50,95 | 115 911 | 4 996 666 | |
2012-06-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 100 | 95 795 | −4,10 | 61,21 | −250 961 | 5 863 612 | |
2012-06-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 900 | 99 895 | −1,87 | 61,21 | −116 301 | 6 114 673 | |
2012-03-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 5 948 | 5 948 | |||||
2012-03-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −5 818 | 0 | −100,00 | ||||
2012-03-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −1 525 | 0 | −100,00 | ||||
2012-03-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −5 948 | 101 795 | −5,52 | 60,39 | −359 200 | 6 147 400 | |
2012-03-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 5 818 | 107 743 | 5,71 | 47,82 | 278 217 | 5 152 270 | |
2012-03-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 1 525 | 101 925 | 1,52 | 33,23 | 50 678 | 3 387 110 | |
2012-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 100 400 | −0,20 | 56,70 | −11 341 | 5 693 182 | |
2012-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 100 600 | −0,20 | 56,70 | −11 340 | 5 704 070 | |
2012-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −467 | 100 800 | −0,46 | 56,70 | −26 479 | 5 715 461 | |
2012-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −40 | 101 267 | −0,04 | 56,70 | −2 268 | 5 742 041 | |
2012-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −10 259 | 101 307 | −9,20 | 57,04 | −585 173 | 5 778 551 | |
2012-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 44 000 | 44 000 | |||||
2012-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 24 400 | 111 566 | 27,99 | ||||
2012-02-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −21 281 | 0 | −100,00 | ||||
2012-02-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 87 166 | −0,91 | 54,24 | −43 393 | 4 727 945 | |
2012-02-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 87 966 | −0,90 | 54,24 | −43 392 | 4 771 293 | |
2012-02-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 88 766 | −0,34 | 54,24 | −16 272 | 4 814 677 | |
2012-02-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −19 381 | 89 066 | −17,87 | 54,24 | −1 051 225 | 4 830 940 | |
2012-02-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 21 281 | 108 447 | 24,41 | 53,62 | 1 141 194 | 5 815 470 | |
2005-06-03 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
31 972 | ||||||||
2005-06-03 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
1 084 |